Disclosures of the American Journal of Psychiatry editors are published in each January issue. Dr. Ross owns stock in Johnson and Johnson. Dr. Appelbaum is a shareholder of COVR, which produces violence risk-assessment software. Dr. Carpenter reports financial interests with Pfizer, Solvay/Wyeth, AstraZeneca, Eli Lilly, and Cephalon. Dr. Rosenbaum has been on the speaker’s bureaus of AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Forest, GlaxoSmithKline, Janssen, Eli Lilly, MedAvante, Novartis, Orexigen, Pfizer, Roche Diagnostics, Sanofi, Shire, Somerset, Sepracor, and Wyeth; has consulted for Compellis, EPIX, Neuronetics, Organon, Somaxon, and Supernus; has received honoraria from Boehringer-Ingelheim, Bristol-Myers Squibb, Cyberonics, Forest, Eli Lilly, and Schwartz; and has equity holdings in Compellis, MedAvante, and Somaxon. The Massachusetts General Hospital Psychiatry Academy is sponsored by AstraZeneca, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, Eli Lilly, and Wyeth. Dr. Freedman has reviewed their contributions to this editorial and found no evidence of influence from these relationships. All other authors report no competing interests.